[ad_1]
Innovative treatment could protect hundreds of millions of people from the "21st century epidemic" caused by life-threatening diabetic kidney failure.
Research conducted in Australia and the United Kingdom has shown that a drug that lowers blood sugar once a day, canagliflozin, reduced the cases of renal failure and the number of deaths of a third in diabetic patients.
According to researchers, nearly five million diabetics in the UK and diabetic kidney disease cost the NHS up to £ 927 million a year. However, there have been no new treatments for nearly two decades.
"There are more than 400 million people with diabetes in the world, and about 40% of them will be suffering from kidney disease," said Professor Vlado Perkovic, lead author of the 39, study, the executive director of the George Institute for Global Health.
"Once they have kidney disease, they run a very high risk of kidney failure, heart attack, stroke and death."
Diabetic kidney failure is caused by years of poorly controlled blood sugar, damaging the blood vessels of the kidneys and impairing its ability to cleanse the blood of salts, proteins, and other wastes that can cause lesions.
In addition to increasing the risk of death from various cardiovascular diseases, people with kidney failure may need regular dialysis sessions to wash their blood.
To test the effects of canagliflozin, the authors enrolled 4,401 patients with diabetes and kidney disease in 34 countries. They randomly badigned them to receive either canaglifozine or placebo in addition to their regular diabetes treatment.
The trial was stopped early because its high success rate meant that leaving some participants under placebo was unethical.
His findings, published in the "New England Journal of Medicine," show that more than two and a half years of kidney failure and death have dropped by 34% compared to the placebo group. (© Independent News Service)
Independent Irish
[ad_2]
Source link
